48 citations,
January 2002 in “Dermatology” Hair pain is more common in women with hair loss, but it's not linked to the cause or severity of hair loss.
46 citations,
September 2003 in “International Journal of Dermatology” Trichodynia found in 29% of TE or AGA patients, linked to psychological conditions.
39 citations,
August 2021 in “JAAD International” COVID-19 patients often experience hair loss and scalp pain, which may be related to the severity of their infection and treatment drugs.
33 citations,
April 2009 in “Clinical and Experimental Dermatology” Psychological factors like depression may be more important than zinc, folate, and vitamin B12 levels in causing scalp pain in people with hair loss.
26 citations,
December 2015 in “International Journal of Dermatology” Trichodynia is a painful scalp condition linked to hair loss and inflammation, often with anxiety, affecting more women and needing better treatment options.
24 citations,
March 2009 in “Journal of the European Academy of Dermatology and Venereology” Scalp pain is a common symptom in people with active hair loss from telogen effluvium.
18 citations,
April 2021 in “Experimental Dermatology” COVID-19 may cause hair loss and scalp pain due to inflammation and changes in hair follicle receptors, but these symptoms typically resolve in 2 to 4 months.
16 citations,
December 2012 in “The Clinical Journal of Pain” Chronic scalp pain in trichodynia involves both body-wide and localized increased pain sensitivity.
10 citations,
January 2012 in “International Journal of Trichology” The study found no link between anxiety, vitamin B12, folate, TSH, ferritin, zinc levels, and trichodynia in telogen alopecia patients.
9 citations,
January 2013 in “Acta dermato-venereologica” The conclusion is that "trichoknesis" should be recognized as a separate condition from trichodynia, characterized by itching instead of pain.
8 citations,
September 2015 in “Journal of the European Academy of Dermatology and Venereology” Hair and scalp pain is more common and severe in breast cancer patients on chemotherapy than those on tamoxifen.
6 citations,
January 2021 in “Journal of Cosmetic Dermatology” Poor sleep during the pandemic may increase stress and worsen hair loss conditions.
4 citations,
January 2021 in “Skin appendage disorders” Trichodynia is a painful scalp condition not directly linked to the amount or type of hair loss and may involve psychological factors, with treatments showing mixed results.
Onabotulinumtoxin-A effectively treated a painful scalp condition when other treatments failed.
Hair loss after COVID-19 is common, starts sooner in severe cases, and often comes with scalp pain.
January 2022 in “Journal of Skin and Stem Cell” Trichodynia is a painful scalp condition needing targeted treatments beyond symptom management.
April 2017 in “InTech eBooks” Many people with hair loss experience scalp pain known as trichodynia, but the causes are unclear and treatments vary.
January 2016 in “International Journal of Medical Research and Health Sciences” People with hair loss conditions like Telogen Effluvium and Alopecia Areata often feel scalp pain and are more likely to have anxiety, but not necessarily depression.
March 2012 in “Journal of The American Academy of Dermatology” Higher levels of certain nerve-related proteins are linked to hair loss in women with scalp pain.
7 citations,
January 1998 in “PubMed” Hair loss can cause scalp discomfort.
September 2024 in “Actas Dermo-Sifiliográficas” Trichodynia is a painful scalp condition linked to hair loss and mental health issues, with limited treatment options.
80 citations,
March 2008 in “Contact Dermatitis” Nearly half of the French individuals surveyed reported having a sensitive scalp, more common in women, often linked to hair loss and symptoms like itching, and triggered by factors including shampoos and pollution.
56 citations,
August 2019 in “Clinical, Cosmetic and Investigational Dermatology” The document concludes that Telogen Effluvium is a hair loss disorder that can be assessed with the modified wash test and may be treated with clobetasol foam, with patient management being important.
45 citations,
January 2015 in “Dermatology” Hair loss in secondary syphilis is more common than thought and can be reversed with antibiotics.
32 citations,
January 1997 in “Dermatology” Telogen effluvium is a hair loss condition with acute cases resolving quickly and chronic cases potentially lasting longer, sometimes requiring treatment.
20 citations,
November 2012 in “Journal der Deutschen Dermatologischen Gesellschaft” Hair diseases can have psychological effects and should be treated with a combination of psychosomatic care, therapy, and medication.
18 citations,
January 2016 in “Skin appendage disorders” The paper suggests improving diagnosis and treatment of telogen effluvium but does not recommend a new classification system.
14 citations,
April 2021 in “Clinical, Cosmetic and Investigational Dermatology” COVID-19 may trigger sudden temporary hair loss.
10 citations,
August 2011 in “Clinics” The author clarified that Alopecia Areata Incognita (AAI) and diffuse Alopecia Areata (AA) are different conditions and the case discussed was actually AA, not AAI.
4 citations,
January 2019 in “Dermatology Online Journal” Low-dose naltrexone might be a cheap and effective additional treatment for hair loss with scalp discomfort due to its anti-inflammatory effects and few side effects.